RNA Avidity Biosciences Inc

$70.56

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

In the rapidly evolving biotech landscape, Avidity Biosciences stands out with its robust market cap of approximately $4.3 billion, reflecting strong investor confidence despite the absence of recent news. As the company approaches its earnings announcement on August 12, analysts are keenly observing its ability to meet the EPS estimate of $0.00, which aligns with the whisper number, suggesting stable expectations. The anticipated revenue of $1.49 million will be a critical indicator of Avidity's progress in advancing its innovative RNA-based therapies. Investors will be particularly interested in any strategic updates that could signal future growth trajectories or partnerships, as these could significantly impact market sentiment and the company's valuation.

Updated On 11/21/2025

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.

Website: https://www.aviditybiosciences.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1599901
Address
10975 N. TORREY PINES RD.,, #150, LA JOLLA, CA, US
Valuation
Market Cap
$3.20B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
2.25
Performance
EPS
$-2.89
Dividend Yield
—
Profit Margin
0.00%
ROE
-33.50%
Technicals
50D MA
$30.11
200D MA
$38.10
52W High
$56.00
52W Low
$21.51
Fundamentals
Shares Outstanding
120M
Target Price
$66.69
Beta
1.01

RNA EPS Estimates vs Actual

● Estimated
● Actual

RNA News & Sentiment

Nov 21, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Nov 20, 2025 • Benzinga SOMEWHAT-BULLISH
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Novartis ( NYSE:NVS )
Novartis AG ( NYSE:NVS ) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.
Nov 20, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR ...
Nov 19, 2025 • Benzinga SOMEWHAT-BULLISH
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences ( NASDAQ:RNA ) has outperformed the market over the past 5 years by 6.63% on an annualized basis producing an average annual return of 19.41%. Currently, Avidity Biosciences has a market capitalization of $10.62 billion.
Nov 19, 2025 • Benzinga SOMEWHAT-BULLISH
Looking Into Avidity Biosciences Inc's Recent Short Interest - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences Inc's ( NYSE:RNA ) short interest as a percent of float has fallen 49.24% since its last report. According to exchange reported data, there are now 10.50 million shares sold short, which is 7.02% of all regular shares that are available for trading.
Nov 18, 2025 • Zacks Commentary NEUTRAL
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Sentiment Snapshot

Average Sentiment Score:

0.186
50 articles with scored sentiment

Overall Sentiment:

Bullish

RNA Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
-0.25 Surprise
  • Reported EPS: $-1.21
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: -26.5%
May 08, 2025
Mar 31, 2025 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.90
  • Estimate: $-0.88
  • Whisper: —
  • Surprise %: -2.2%
Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-0.78
  • Whisper: —
  • Surprise %: -2.5%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 8.4%
Aug 09, 2024
Jun 30, 2024 (Post market)
0.14 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.79
  • Whisper: —
  • Surprise %: 17.7%
May 09, 2024
Mar 31, 2024 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.78
  • Whisper: —
  • Surprise %: -1.3%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.66
  • Whisper: —
  • Surprise %: -19.7%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $-0.71
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: 7.8%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.14 Surprise
  • Reported EPS: $-0.66
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: 17.5%

Financials